Chelsea Therapeutics Rises as Northera Wins Panel Backing
This article is for subscribers only.
Chelsea Therapeutics International Ltd. surged the most in almost seven years after the company’s drug to treat a condition that can cause dizziness in people with central nervous system disorders won the backing of a U.S. advisory panel.
Chelsea Therapeutics climbed 61 percent to $3.88 at the close in New York, its biggest increase since June 2005. Shares of the Charlotte, North Carolina-based company had fallen 41 percent in the 12 months before today.